# Compare CJC-1295, Ipamorelin, KPV, Retatrutide, and Semaglutide — Best Peptide

> A side-by-side evidence-maturity comparison of five Research Peptide Fundamentals research peptides — mechanism, most-studied application, trial depth, regulatory status, and the single biggest caution for each.

Mechanism, most-studied application, evidence maturity, regulatory status, and the single biggest caution for each — read side by side rather than compound by compound.

## The short version

This page lines up [CJC-1295](/cjc-1295), [ipamorelin](/ipamorelin), [KPV](/kpv), [retatrutide](/retatrutide), and [semaglutide](/semaglutide) on the dimensions that actually determine how much confidence a reader should place in a claim: what receptor or pathway each one targets, what it has been most studied for, how mature that evidence really is (rodent-only, single human trial, or repeated large trials), how it has been administered in the studies that exist, its regulatory status, and the one caution most worth remembering about each. The short version of the long version below: evidence maturity does not track neatly with how often a compound is discussed in research-peptide communities. KPV, the least discussed of the five in mainstream weight-loss circles, has the cleanest mechanistic story; semaglutide, the most discussed and most heavily marketed, also happens to have, by a wide margin, the strongest human trial record. None of this is medical advice, and no dose is recommended anywhere on this page.

## The comparison matrix

| Dimension | CJC-1295 | Ipamorelin | KPV | Retatrutide | Semaglutide |
| --- | --- | --- | --- | --- | --- |
| Target / class | GHRH receptor agonist (GH secretagogue) | Ghrelin receptor (GHS-R1a) agonist | Melanocortin-derived anti-inflammatory tripeptide | GIP/GLP-1/glucagon triple receptor agonist | GLP-1 receptor agonist |
| Most studied for | GH/IGF-1 elevation pharmacokinetics | Postoperative gut motility; GH release | Intestinal (colitis) inflammation | Obesity, type 2 diabetes, metabolic liver disease | Type 2 diabetes, obesity, cardiovascular & kidney outcomes |
| Human efficacy trials | None | One RCT — missed primary endpoint [8] | None published | Phase 2 only, ongoing Phase 3 [19][20] | Multiple large Phase 3 outcome trials [21][22][23][24] |
| Deepest evidence | Small human PK/pharmacology studies [3][4][5] | Human PK study + one RCT [8][9] | Mouse colitis models, in vitro mechanism [11][13][14] | Phase 2 RCTs, ~280-340 participants each [19][20] | Phase 3 RCTs, hundreds to 17,000+ participants [21][23][24] |
| Regulatory status | Not approved anywhere; research chemical | Not approved anywhere; research chemical | Not approved anywhere; research chemical | Investigational; not approved anywhere as of 2026 | FDA-approved (multiple indications) |
| Biggest single caution | No efficacy trial has ever tested its marketed uses | Its only human trial did not meet its goal | No human trial exists at all | Unapproved, unverified gray-market supply; dose-dependent heart-rate signal [19] | Even the best-evidenced compound here lost its own head-to-head trial [21] |

## Target and mechanism

The five compounds sit on genuinely different biological pathways, which is part of why lumping them together as 'research peptides' obscures more than it clarifies. CJC-1295 and ipamorelin both aim at growth-hormone release, but through different receptors — GHRH receptor and ghrelin receptor, respectively — which is the stated rationale for using them together, though that combination itself has never been trial-tested. KPV works through an entirely separate anti-inflammatory pathway centered on NF-kB and MAP-kinase suppression, delivered via a gut transporter rather than a classical hormone receptor [13]. Retatrutide and semaglutide both work through incretin biology, with retatrutide adding two additional receptor targets (GIP and glucagon) on top of the single GLP-1 target semaglutide occupies [17].

## Evidence maturity — the dimension that matters most

This is where the five genuinely separate, and it is the organizing question of this entire desk. Semaglutide sits at the top: a decade-plus of large, randomized, hard-outcome trials across diabetes, obesity, cardiovascular disease, and kidney disease [21][22][23][24]. Retatrutide is one tier below — real randomized Phase 2 trials with a few hundred participants each, promising numbers, but no completed Phase 3 [19][20]. Ipamorelin has exactly one human randomized trial, and it missed its primary endpoint [8]. CJC-1295 has small human pharmacokinetic studies but zero controlled efficacy trials of any kind [4][5]. KPV has the most internally consistent mechanistic story of the five — replicated across independent studies and multiple mouse models [11][13][14] — and also the least human evidence: none. A reader who only skims marketing copy would likely rank these five in something close to the reverse order of their actual evidence maturity.

## Regulatory and administration status

Semaglutide is the only FDA-approved compound on this desk, available as a prescription weekly injection or daily tablet. Retatrutide is investigational, administered by subcutaneous injection in its Phase 2/3 trials, with no approval anywhere. CJC-1295, ipamorelin, and KPV are, by regulatory status, research chemicals with no approved human indication in any jurisdiction; the human studies that exist for CJC-1295 and ipamorelin used clinical-research dosing under supervision, not the unsupervised subcutaneous protocols common in research-use communities today.

## The single biggest caution for each

For **CJC-1295**, it is simply that no efficacy trial exists for any of its marketed uses — the pharmacology is real, the outcomes are untested. For **ipamorelin**, it is that its one human efficacy trial did not meet its own primary endpoint [8], a fact that gets lost in most marketing. For **KPV**, it is the complete absence of human trial data of any kind — a promising rodent mechanism is not the same claim as a demonstrated human effect. For **retatrutide**, it is unapproved and unverified gray-market supply combined with a documented dose-dependent heart-rate signal that has not been evaluated in a long-term cardiovascular trial [19]. For **semaglutide**, even at the top of this evidence hierarchy, it is that the drug lost its own head-to-head trial against tirzepatide [21] — a reminder that 'best-evidenced' is a statement about trial rigor, not a claim of superiority on every metric.

---

A skeptic's literature desk — we say plainly when the evidence behind a claim is a single small trial, a rat model, or nothing but community anecdote, before we say anything else.